MLL Munich Leukemia Laboratory buys Fluidigm (Caltech) Access Array™ & Ep1™ Systems (11/16/2010)

Fluidigm was founded in 1999 to commercialize IFC technology developed by Dr. Stephen Quake when he was at Caltech.

From the company’s press release:
Fluidigm Corporation announced today that MLL Munich Leukemia Laboratory ( has purchased Access Array™ and EP1™ Systems. The Access Array System is being used in combination with Roche’s 454 GS FLX and GS Junior sequencing instruments, enabling high-throughput targeted deep-resequencing analyses. The EP1 System is being used for rare mutation detection studies and minimal residual disease investigations. read full press release


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: